BioClonal R&D programs

BioClonal seeks to create value and growth.

RedMabs novel technology is being applied to the development of monoclonals against a novel target for Alzheimer's Disease, unreachable until now. A new target has been discovered by Javier Garfella, Chief Scientific Officer at Bioclonal, with more than 40 years of experience in immunology and Alzheimer's Disease molecular mechanisms. Novel target presented here is related to a structure of 42-residue human amyloid β (Aβ 1-42) named by BioClonal as AB-BC. Access to this kind of protein had not been possible with standard technologies. However, the RedMambs platform opens the chance for Rational Antibody Discovery for AB- BC. Monoclonals designed and developed by RedMabs will constitute the base for a differential diagnosis and preventive and curative treatment for such a relevant pathology as Alzheimer's Disease.,